The CTC offices are currently closed for refurbishment. Access to trial TMFs and patient records will be limited during this period. We will still be able to receive post during this time, but there may be a small delay in responding to this. Our fax lines may also be subject to disruption. Where possible, please direct all correspondence via email to trial-specific email addresses. We appreciate your patience and understanding.

Due to COVID-19 and current government guidance, UCL CTC staff continue to work remotely with limited access to the office. Please continue to email the trial specific mailbox with any urgent queries. For paper CRF trials, please continue to copy and scan CRFs to the trial inboxes (remove all patient identifiers except Trial Number and Initials) until further notice.

 
Ovarian cancer study recruits 200th patient
09 March 2020
This year has seen ovarian cancer study ICON9 register its 200th patient, with now over 100 patients randomised to receive study medication.  
 
A CR UK flagship study run by the CR UK and UCL Cancer Trials Centre and supported by AstraZeneca, ICON9 is a phase III study investigating the effectiveness of combination maintenance therapy in patients with ovarian cancer who have relapsed. Patients who are shown to respond to their second-line, platinum-based chemotherapy are approached for the trial if they are eligible, and randomised to receive either both Olaparib – a “PARP inhibitor” - and Cediranib – an “anti-angiogenesis” drug, or Olaparib alone.   
 
Angiogenesis (the development of new blood vessels) and the enzyme PARP (which enables cancer cells to repair their DNA and continue to divide) play a role in the growth of ovarian cancer. Cediranib and Olaparib have both been shown to delay tumour progression, and ICON9 is investigating the effectiveness and safety of using both medications together in recurrent ovarian cancer. 

Trial Coordinator Ian Macdonald, who joined the CTC in December, said: “I am excited to have joined the fantastic team at the CTC and been given the opportunity to work on this flagship study, which has the potential to improve the treatment options of women with recurrent ovarian cancer.” 
 
There are currently just under 40 sites recruiting patients in the UK, Australia and New Zealand, with more sites across the world slated to open later this year.


Image: Ovarian cancer cells, Ed Uthman
Contact Us
Cancer Research UK & UCL Cancer Trials Centre
University College London
90 Tottenham Court Road
London
W1T 4TJ

View map
Email:
ctc.enquiries@ucl.ac.uk
Telephone:
+44 (0)20 7679 9898 (General CTC Enquiries)
Fax:
020 7679 9899
University College London, Gower Street, London, WC1E 6BT +44 (0)20 7679 2000

Copyright © 2021 UCL | Disclaimer | Freedom of Information | Accessibility | Privacy | Cookies | Contact Us